Systemic candidiasis treatment adjunct

Systemic candidiasis treatment adjunct describes a therapeutic setting rather than a distinct primary diagnosis, referring to supplemental therapies administered alongside primary systemic antifungal regimens for invasive or disseminated candidiasis

Systemic candidiasis treatment adjunct describes a therapeutic setting rather than a distinct primary diagnosis, referring to supplemental therapies administered alongside primary systemic antifungal regimens for invasive or disseminated candidiasis In this setting, adjunctive interventions target complicating features such as infected intravascular thrombi, device biofilms, or ocular lesions to improve clearance alongside standard systemic antifungal pharmacotherapy

Systemic candidiasis treatment adjunct describes a therapeutic setting rather than a distinct primary diagnosis, referring to supplemental therapies administered alongside primary systemic antifungal regimens for invasive or disseminated candidiasis Systemic candidiasis is a severe, life-threatening infection typically caused by *Candida* species—such as *Candida albicans*, *Nakaseomyces glabrata*, or *Candida tropicalis*—that hematogenously disseminate to sterile tissues, deep visceral organs, ...

Systemic candidiasis is a severe, life-threatening infection typically caused by *Candida* species—such as *Candida albicans*, *Nakaseomyces glabrata*, or *Candida tropicalis*—that hematogenously disseminate to sterile tissues, deep visceral organs, the central nervous system, or the bloodstream, predominantly affecting critically ill, hospitalized, or immunocompromised patients Clinically and pathophysiologically, it is characterized by persistent fungemia, systemic inflammatory response, deep-...

Systemic candidiasis is a severe, life-threatening infection typically caused by *Candida* species—such as *Candida albicans*, *Nakaseomyces glabrata*, or *Candida tropicalis*—that hematogenously disseminate to sterile tissues, deep visceral organs, the central nervous system, or the bloodstream, predominantly affecting critically ill, hospitalized, or immunocompromised patients

Clinically and pathophysiologically, it is characterized by persistent fungemia, systemic inflammatory response, deep-tissue microabscesses, or focal end-organ damage

In this setting, adjunctive interventions target complicating features such as infected intravascular thrombi, device biofilms, or ocular lesions to improve clearance alongside standard systemic antifungal pharmacotherapy